ATE212231T1 - Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie - Google Patents

Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie

Info

Publication number
ATE212231T1
ATE212231T1 AT95926883T AT95926883T ATE212231T1 AT E212231 T1 ATE212231 T1 AT E212231T1 AT 95926883 T AT95926883 T AT 95926883T AT 95926883 T AT95926883 T AT 95926883T AT E212231 T1 ATE212231 T1 AT E212231T1
Authority
AT
Austria
Prior art keywords
tnf receptor
steroid hormone
combination therapy
relates
treatment
Prior art date
Application number
AT95926883T
Other languages
English (en)
Inventor
Alessandra Boe
Francesco Borrelli
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE212231T1 publication Critical patent/ATE212231T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95926883T 1995-07-14 1995-07-14 Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie ATE212231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/002767 WO1997003686A1 (en) 1995-07-14 1995-07-14 Tnf receptor and steroid hormone in a combined therapy

Publications (1)

Publication Number Publication Date
ATE212231T1 true ATE212231T1 (de) 2002-02-15

Family

ID=8166058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926883T ATE212231T1 (de) 1995-07-14 1995-07-14 Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie

Country Status (11)

Country Link
US (1) US6225300B1 (de)
EP (1) EP0839046B1 (de)
JP (1) JP4011618B2 (de)
AT (1) ATE212231T1 (de)
AU (1) AU715260B2 (de)
DE (1) DE69525181T2 (de)
DK (1) DK0839046T3 (de)
ES (1) ES2171547T3 (de)
IL (1) IL118789A0 (de)
WO (1) WO1997003686A1 (de)
ZA (1) ZA965891B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012060B1 (en) * 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
NL1006876C2 (nl) 1997-08-28 1999-03-02 Schiphol Luchthaven Nv Platform voor het parkeren en afhandelen van vliegtuigen.
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1450839A4 (de) * 2001-11-06 2009-06-24 Serono Lab Verfahren zur behandlung von auf östrogen ansprechendem brustkrebs
US7674453B2 (en) 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
CA2100329C (en) * 1991-01-18 2009-09-29 David F. Carmichael Methods for treating tumor necrosis factor mediated diseases
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるtnf−依存性炎症の治療方法
AU4719093A (en) 1993-07-30 1995-02-28 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis

Also Published As

Publication number Publication date
ES2171547T3 (es) 2002-09-16
DE69525181D1 (de) 2002-03-14
DE69525181T2 (de) 2002-08-14
IL118789A0 (en) 1996-10-31
AU715260B2 (en) 2000-01-20
DK0839046T3 (da) 2002-02-18
ZA965891B (en) 1997-03-19
EP0839046B1 (de) 2002-01-23
WO1997003686A1 (en) 1997-02-06
JPH11509213A (ja) 1999-08-17
US6225300B1 (en) 2001-05-01
AU3110995A (en) 1997-02-18
EP0839046A1 (de) 1998-05-06
HK1009403A1 (en) 1999-06-04
JP4011618B2 (ja) 2007-11-21

Similar Documents

Publication Publication Date Title
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
EA200201000A1 (ru) Гормон-заместительная терапия
MD1920F2 (ro) Compoziţie şi metodă de profilaxie sau frânare a debutului bolii Alzheimer
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
MY131522A (en) PHARMACEUTICAL COMPOSITION AND USES FOR ANDROST-5-ENE-3ß,17ß-DIOL
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
YU69000A (sh) Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
TR199802705T2 (xx) Progestojen-anti-progestojen k�r�
EP0902789A4 (de)
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
CA2454339A1 (en) Methods for preventing antipsychotic-induced weight gain
BR9710566A (pt) M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
CA2504697A1 (en) Methods for treating migraine
EP0663835A1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft.
DE69525181D1 (de) Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
CA2459033A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee